Obatoclax is an early pan-BCL-2 inhibitor that can antagonize BCL-2, BCL-xl, BCL-w, and MCL-1 and promote the activation of Bax/Bak and subsequent caspase-3 activation, ultimately leading to the apoptosis of tumor cells. Here, BCL2 is linked to neoplasm.